30 closest matches · ranked by relevance
Warm Autoimmune Hemolytic Anemia · Cold Agglutinin Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 5; 5; 7; 6 Participants
Cold Agglutinin Disease
Primary: Number of Patients Achieving a Response (R) at Week 24 — 8; 2 Participants
Agglutinin Disease, Cold
Primary: Part A: Percentage of Participants With Response to Treatment — 54.2 percentage of participants
Cold Agglutinin Disease
Primary: Part A: Percentage of Participants With Response to Treatment — 72.7; 15.0 percentage of participants — p=<0.001
Cold Agglutinin Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 7; 1 Participants
Immune Thrombocytopenic Purpura
Primary: Set of Antibodies Most Frequently Bound to Red Blood Cells (RBCs) in Subjects Experiencing Clinically Significant Intravascular Hemolysis
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Multiple Myeloma · Plasma Cell Neoplasm
Primary: Tolerance for Human Immune Globulin Intravenous (IGIV), as Reflected by the Number and Severity of Toxicity Incidents Occurring in Ten Patients Receiving at Least One…
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Warm Antibody Autoimmune Hemolytic Anemia
Primary: Durable Hemoglobin Response — 16; 12 Participants
Familial Cold Autoinflammatory Syndrome (FCAS) · Familial Cold Urticaria · Muckle-Wells Syndrome (MWS)
Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Hepatitis C · Vasculitis
Primary: Percent of Patients in Remission — 83; 8 percent of participants
Macular Degeneration
Primary: Mean Change in Visual Acuity (Logarithm of the Minimum Angle of Resolution [LogMAR]) Score From Baseline for IGIV-C, 10% Compared to Placebo at Week 12 or at Last LogMAR…
Chronic Lymphocytic Leukemia
Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Autoimmune Pancytopenia · Autoimmune Lymphoproliferative Syndrome (ALPS) · Evans Syndrome
Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants
Celiac Disease
Primary: Number of Participants for Which Treatment Was Concluded to be Safe — 6; 18; 4; 5 participants
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Primary: %Survival — 44; 7 percentage of participants
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Autoimmune Autonomic Ganglionopathy (AAG)
Primary: Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) — 42.5; -12.3 mmHg
Leukemia · Chronic Lymphocytic Leukemia
Primary: Overall Participant Response — 44; 1; 10 Participants
Secondary Immunodeficiencies (SID)
Primary: Guideline Adherence (GLAD) — 889; 75; 122 Participants
Sickle Cell Disease
Primary: Proportion of Biochemically Old Red Cell Units — 0.71; 0.86 proportion biologically old units — p=0.051
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Primary: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period — 54.2; 20.7 percentage of responders — p=<0.001
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
Antibody Mediated Rejection of Kidney Transplant
Primary: Renal Allograft Survival Measured by Severe and Refractory Antibody Mediated Renal (AMR) — 1 Participants
Primary Immunodeficiency
Primary: Annual Rate of Occurrence of Serious Bacterial Infections (SBI) — 0; 0.01; 0; 0.03 Rate of events per subject per year
Lymphoma
Primary: Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study — 0; 0; 0; 0 percentage of participants
Raynaud Phenomenon · Systemic Sclerosis
Primary: Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography — 19558.43; 20045.96 C*sec — p==0.3801